Technology thesis · Biotechnology & Health
medium conviction emergingOrgans-on-chips
The FDA's 2025 animal-testing roadmap turns organs-on-chips from a research curiosity into a preclinical standard this decade, but reproducibility and thin platform revenue keep it a slow burn, not a 2026 breakout.
Position maintained continuously · last reviewed Jun 24, 2026
The thesis
Core thesis
Organs-on-chips model drug metabolism, toxicity, and efficacy using human cells under physiological flow. Emulate (co-founded by Donald Ingber) remains the reference platform vendor. The regulatory pull is no longer just the FDA Modernization Act 2.0 (2022): the FDA published its Roadmap to Reducing Animal Testing in April 2025, reported meeting year-one goals in April 2026, and the FDA Modernization Act 3.0 cleared the Senate in December 2025. Adoption is real but still mostly supplements rather than replaces animal models; reproducibility and thin platform revenue keep it a slow burn.
State of the art (2026)
The regulatory tailwind is now concrete rather than aspirational. The FDA published its Roadmap to Reducing Animal Testing in April 2025 and reported meeting year-one goals in early 2026, with draft guidance (December 2025) on cutting non-human-primate studies for monoclonal antibodies. The Senate passed the FDA Modernization Act 3.0 by unanimous consent in December 2025; the House version cleared committee in May 2026, which would force the FDA to rewrite IND rules to recognise non-animal data. Commercially the field is still small (roughly $390M in 2025) and consolidating: Emulate launched its 96-chip AVA high-throughput system in June 2025 and showcased it at SLAS2026, while Hesperos folded into Javelin Biotech. Liver and gut chips lead on validation; multi-organ body-on-chip reproducibility is what still blocks routine pharma use.
Everything below is live inside CanaryIQ
The full analysis behind the verdict — the structure is real; the content unlocks when you log in.
Signal stack
Evidence stacked leading → lagging
Technology-native KPIs
Metrics that predict trajectory, tracked over time
Landscape map
Who builds what — and who depends on whom
Catalyst calendar
Dated events that will move the position
Technology roadmap
Milestones on the path to maturity
Watchlists
Companies, people and papers — each with a remove-by condition
Decision frameworks
The same call, framed for your desk
Thesis changelog
When our view changed, and why
Change our mind
3 disconfirming conditions
The rest is inside
You've read the verdict. The file is much deeper.
The full signal stack, technology-native KPIs tracked over time, the landscape of who depends on whom, the dated catalyst calendar, decision frameworks for every desk, live watchlists and the changelog of every time our call on Organs-on-chips has changed — all live inside CanaryIQ.